Antibodies and antibody derivatives constitute 20 % of biopharmaceutical products currently in development, and despite early failures of murine products, chimeric and humanized monoclonal antibodies...

Antimicrobial resistance is one of the most worrying threats to humankind with extremely high healthcare costs associated. The current technologies used in clinical microbiology to identify the bacterial agent and profile antimicrobial susceptibility are time‐consuming and frequently expensive. As a result, physicians prescribe empirical antimicrobial therapies. This scenario is often the cause of therapeutic failures, causing higher mortality rates and healthcare costs, as well as the emergence and spread of antibiotic resistant bacteria. As such, new technologies for rapid identification of the pathogen and antimicrobial susceptibility testing are needed. This review summarizes the current technologies, and the promising emerging and future alternatives for the identification and profiling of antimicrobial resistance bacterial agents, which are expected to revolutionize the field of clinical diagnostics.

Animals' olfactory systems rely on proteins, olfactory receptors (ORs) and odorant-binding proteins (OBPs), as their native sensing units to detect odours. Recent advances demonstrate that these proteins can also be employed as molecular recognition units in gas-phase biosensors. In addition, the interactions between odorant molecules and ORs or OBPs are a source of inspiration for designing peptides with tunable odorant selectivity. We review recent progress in gas biosensors employing biological units (ORs, OBPs, and peptides) in light of future developments in artificial olfaction, emphasizing examples where biological components have been employed to detect gas-phase analytes.